Michele Donovan, OD
Optometrist · Charleston, SCNPI 1336130095
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,548 of the $6,880 with a category attached, or 66.1%. 18 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 37.1% of the total. Reporting peaked in 2022 at $2,706 and has fallen 70.2% since, to $807 in 2025. Among optometrist clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $89.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$3K
- Alcon$1K
- Bausch & Lomb Americas Inc.$551
- Sun Pharmaceutical Industries Inc.$449
- Optos, Inc.$247
- Mallinckrodt Hospital Products Inc.$237
- plus $2K from 12 others
What the payments were for
- Consulting fees$1,98529%
- Food & beverage$4,54866%
- Education$1001%
- Entertainment$2474%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 14 | $2,551 |
| Alcon | 17 | $1,140 |
| Bausch & Lomb Americas Inc. | 8 | $551 |
| Sun Pharmaceutical Industries Inc. | 4 | $449 |
| Optos, Inc. | 3 | $247 |
| Mallinckrodt Hospital Products Inc. | 4 | $237 |
| Amgen | 2 | $219 |
| Biotissue Holdings Inc. | 2 | $199 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $186 |
| Coopervision Inc. | 4 | $172 |
| Oyster Point Pharma, Inc. | 2 | $157 |
| Sight Sciences, Inc. | 2 | $142 |
| Glaukos Corporation | 1 | $137 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $132 |
| Shire North American Group Inc | 1 | $124 |
| AbbVie(2 entities) | 4 | $103 |
| LKC Technologies, Inc. | 1 | $97 |
| Novartis | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$2,088
- TOTAL30$389
- CEQUA$353
- Precision 1$227
- TEPEZZA$219
- CE-marked KXLA system$137
- Rocklatan$126
- SIMBRINZA$126
- Rhopressa$126
- DAILIES TOTAL1$126
- XIIDRA$124
- OMNI(R) SURGICAL SYSTEM (US)$123
- INFUSE$119
- BIOTRUE$119
- Tecnis IOL$117
- VYZULTA$109
- P200DTx$100
- P200T$100
- P200TE$100
- P200TxE$100
How this compares
$6,880 in reported general payments places this provider in the 95th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TyrvayaVarenicline Tartrate | 16 | $11,308 |
| XiidraLifitegrast | 12 | $8,195 |
| LumiganBimatoprost | 23 | $6,593 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $4,691 |
| Cyclosporine | 11 | $3,353 |
| TafluprostTafluprost/Pf | 25 | $2,808 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $1,668 |
| Latanoprost | 73 | $495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Oyster Point Pharma, Inc.Tyrvaya | $157 | $11,30816 claims |
| AbbVieLumigan, Combigan | $103 | $11,28337 claims |
| Bausch & Lomb Americas Inc.Xiidra | $551 | $8,19512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Charleston
- Richard BedellCharleston$55K
- Jennifer ZolmanCharleston$21K
- Michael ZolmanCharleston$14K
- Chad CarlssonCharleston$13K
- William DentonCharleston$7K
- Elyse DewittCharleston$6K
- Jensen RafoolCharleston$6K
- Alexa RoweCharleston$6K
- Thomas WeshefskyMyrtle Beach$77K
- Patrick VollmerColumbia$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.